Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, Martin [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15938
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [1] Tildrakizumab efficacy by metabolic syndrome status in psoriasis: 3-year data from the phase 3 reSURFACE 1 study
    Lebwohl, M. G.
    Mehta, N. N.
    Gottlieb, A. B.
    Rozzo, S.
    Parno, J.
    Rozzo, S. J.
    Menter, A. M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 91 - 91
  • [2] Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2
    Fernandez, A. P.
    Dauden, E.
    Gerdes, S.
    Lebwohl, M. G.
    Menter, M. A.
    Leonardi, C. L.
    Gooderham, M.
    Gebauer, K.
    Tada, Y.
    Lacour, J. P.
    Bianchi, L.
    Egeberg, A.
    Pau-Charles, I.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Mehta, N. N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) : 1774 - 1783
  • [3] Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 519 - 522
  • [4] The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
    Menter, M. Alan
    Mehta, Nehal N.
    Lebwohl, Mark G.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Leonardi, Craig
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 703 - 708
  • [5] The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: Post hoc analysis of 2 phase 3 trials (reSURFACE 1 and reSURFACE 2)
    Mehta, Nehal N.
    Lebwohl, Mark G.
    Leonardi, Craig
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Myers, Jill
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB131 - AB131
  • [6] Effect of metabolic syndrome on efficacy and safety in patients with psoriasis treated with etanercept or tildrakizumab: Post hoc analysis of 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
    Gottlieb, Alice B.
    Mehta, Nehal N.
    Lebwohl, Mark
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB50 - AB50
  • [7] Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB51 - AB51
  • [8] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
    Tyring, S.
    Spelman, L.
    Igarashi, A.
    Ohtsuki, M.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Guenthner, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
  • [9] EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND RESURFACE 2
    Gottlieb, A. B.
    Mehta, N.
    Menter, A.
    Mendelsohn, A. M.
    Rozzo, S.
    Lebwohl, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1304 - 1305
  • [10] Relationship of serum glucose to efficacy and safety of tildrakizumab treatment for psoriasis in patients with and without metabolic syndrome from reSURFACE 1 and reSURFACE 2
    Lebwohl, Mark G.
    Menter, Alan
    Rozzo, Stephen J.
    Parno, Jeff
    Mendelsohn, Alan M.
    Mehta, Nehal N.
    Langley, Richard G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB163 - AB163
12345